220 related articles for article (PubMed ID: 29569251)
1. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study.
Harris GE; Wood M; Ystrom E; Nordeng H
Paediatr Perinat Epidemiol; 2018 May; 32(3):247-255. PubMed ID: 29569251
[TBL] [Abstract][Full Text] [Related]
2. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study.
Wood ME; Lapane K; Frazier JA; Ystrom E; Mick EO; Nordeng H
Paediatr Perinat Epidemiol; 2016 Mar; 30(2):190-200. PubMed ID: 26525300
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study.
Wood ME; Frazier JA; Nordeng HM; Lapane KL
BMJ Open; 2016 Sep; 6(9):e011971. PubMed ID: 27625061
[TBL] [Abstract][Full Text] [Related]
4. Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity.
Wood ME; Frazier JA; Nordeng HM; Lapane KL
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):493-502. PubMed ID: 26554750
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis.
Marchenko A; Etwel F; Olutunfese O; Nickel C; Koren G; Nulman I
Headache; 2015 Apr; 55(4):490-501. PubMed ID: 25644494
[TBL] [Abstract][Full Text] [Related]
6. Association of Maternal Use of Triptans During Pregnancy With Risk of Attention-Deficit/Hyperactivity Disorder in Offspring.
Harris GM; Wood M; Ystrom E; Nordeng H
JAMA Netw Open; 2022 Jun; 5(6):e2215333. PubMed ID: 35657626
[TBL] [Abstract][Full Text] [Related]
7. Prenatal paracetamol exposure and neurodevelopmental outcomes in preschool-aged children.
Trønnes JN; Wood M; Lupattelli A; Ystrom E; Nordeng H
Paediatr Perinat Epidemiol; 2020 May; 34(3):247-256. PubMed ID: 31448449
[TBL] [Abstract][Full Text] [Related]
8. Errata in "Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian mother and child cohort study".
Nezvalová-Henriksen K; Spigset O; Nordeng HM
Headache; 2012 Sep; 52(8):1319-20. PubMed ID: 22946832
[No Abstract] [Full Text] [Related]
9. Modeling exposures of medications used episodically during pregnancy: Triptans as a motivating example.
Harris GE; Wood M; Nordeng H
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1111-1119. PubMed ID: 32748540
[TBL] [Abstract][Full Text] [Related]
10. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
[TBL] [Abstract][Full Text] [Related]
11. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.
Nezvalová-Henriksen K; Spigset O; Nordeng H
Headache; 2010 Apr; 50(4):563-75. PubMed ID: 20132339
[TBL] [Abstract][Full Text] [Related]
12. Maternal acetaminophen use during pregnancy and childhood behavioural problems: Discrepancies between mother- and teacher-reported outcomes.
Parker SE; Collett BR; Werler MM
Paediatr Perinat Epidemiol; 2020 May; 34(3):299-308. PubMed ID: 31693212
[TBL] [Abstract][Full Text] [Related]
13. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study.
Brandlistuen RE; Ystrom E; Nulman I; Koren G; Nordeng H
Int J Epidemiol; 2013 Dec; 42(6):1702-13. PubMed ID: 24163279
[TBL] [Abstract][Full Text] [Related]
14. Triptans in pregnancy.
Soldin OP; Dahlin J; O'Mara DM
Ther Drug Monit; 2008 Feb; 30(1):5-9. PubMed ID: 18223456
[TBL] [Abstract][Full Text] [Related]
15. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study.
Spielmann K; Kayser A; Beck E; Meister R; Schaefer C
Cephalalgia; 2018 May; 38(6):1081-1092. PubMed ID: 28758416
[TBL] [Abstract][Full Text] [Related]
17. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
18. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS
Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476
[TBL] [Abstract][Full Text] [Related]
19. Commentary: Triptan use during pregnancy: a safe choice?
Kurth T; Hernandez-Diaz S
Headache; 2010 Apr; 50(4):576-8. PubMed ID: 20456148
[No Abstract] [Full Text] [Related]
20. Behavioural disorders in 6-year-old children and pyrethroid insecticide exposure: the PELAGIE mother-child cohort.
Viel JF; Rouget F; Warembourg C; Monfort C; Limon G; Cordier S; Chevrier C
Occup Environ Med; 2017 Mar; 74(4):275-281. PubMed ID: 28250046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
